Claire Aldridge, PhD, has served as a director since March 2025. Dr. Aldridge currently serves on the Scientific Advisory Board of Colossal Biosciences Inc., Form Bio, Inc. and Exin Therapeutics and on the board of directors of 4E Therapeutics, Inc. and InterAct Therapeutics. Previously, Dr. Aldridge was the Chief Strategy Officer of Form Bio, Inc., the first spinout from the de-extinction and biodiversity company Colossal Biosciences Inc., from July 2022 to August 2024. At Form Bio, Inc., Dr. Aldridge led the integration of artificial intelligence (AI) and machine learning into genomic analysis and advanced therapeutics programs, such as gene therapy, biological sequence alignment, and directed evolution to accelerate the development of safe and effective new medicines. She also oversaw the generation of vast proprietary datasets needed to train sophisticated AI models. Dr. Aldridge also previously served as Senior Vice President, Chief of Staff and Business Operations at Taysha Gene Therapies, Inc. (NASDAQ: TSHA) from July 2021 to April 2022; as Associate Vice President of Commercialization and Business Development at The University of Texas Southwestern Medical Center from April 2019 to February 2021; and as Vice President, Venture Development at Remeditex Ventures from July 2011 to April 2019. Dr. Aldridge sits on the Product Development Advisory Committee of the Cancer Prevention and Research Institute of Texas (CPRIT), the $6 billion state agency established to help Texans conquer cancer through research, prevention, and commercialization. She is also a founding advisor for Nucleate Texas, a non-profit organization empowering the next generation of biotechnology leaders. Additionally, she participates in Duke University s Entrepreneurial Leaders Network, which consists of a select group of Duke students and alumni who are focused on translating Duke discoveries into innovative startups, and is Past Chair of the Industrial Advisory Board of the Department of Bioengineering at The University of Texas at Dallas. In April 2023, Dr. Aldridge was named one of Forbes 10 women leading the synthetic biology revolution. Dr. Aldridge received her PhD from Duke University in the Department of Immunology and the Program in Genetics and Genomics and her Bachelor of Science degree in Biomedical Science from Texas A&M University. Dr. Aldridge brings significant experience applying AI, machine learning, and computational technologies to scientific and therapeutic innovation. At Form Bio, she advanced computational frameworks for large scale genomic analysis and oversaw platforms supporting synthetic biology, genomic engineering, and other data intensive R&D. Her expertise includes developing AI-enabled analytical systems used in comparative genomics, gene therapy, and biotechnology programs; evaluating the digital and infrastructure needs of emerging biotechnology ecosystems; and applying computational tools to accelerate scientific and operational decision-making across the drug development lifecycle. Her expertise in AI-driven genomic analysis, data architecture, and computational biology strengthens the Board s oversight of technology trends affecting the life science and technology sectors. This experience is particularly relevant to genomics, synthetic biology, advanced biomanufacturing, and AI-enabled R&D environments central to the innovation ecosystems served by Alexandria. Dr. Aldridge s background aligns with Alexandria s focus on supporting the increasingly computational and AI-enabled nature of life science R&D. Her insight into how AI is transforming scientific workflows and shaping tenant infrastructure requirements enhances the Board s ability to evaluate emerging technology trends, data-intensive tenant needs, and related innovation, risk, and governance considerations. She also strengthens Board oversight of Alexandria s internal generative AI initiatives, through which the Company is evaluating and implementing AI-enabled solutions that enhance productivity, operational efficiency, and enterprise performance across key business functions. Her background further supports the Company s efforts to responsibly implement AI and to shape a technology strategy that advances long term objectives and responds to the evolving needs of Alexandria and its tenant base. Dr. Aldridge s qualifications to serve on the Board include her 25 years of experience in the biotechnology and life science industries, her venture capital investment expertise, and her leadership in integrating AI and machine learning into genomic analysis and advanced therapeutics programs.